BACKGROUND
The French-American-British (FAB) classification system for myelodysplastic syndrome (MDS) is based largely on morphology, including broad subtypes that crudely correlate with prognosis. The World Health Organization (WHO) scheme includes more extensive morphologic and cytogenetic criteria that are important not only for classification, but also for prognosis and treatment (eg: those with 5q-). Despite this, it is not currently known to what extent the WHO scheme has been adopted by practicing hematologists and pathologists. For patients with documented MDS, WHO subtypes were recorded 40% of the time, compared to 8% for FAB subtypes; this finding from our national cohort bodes well for increasing consistency between MDS researchers and caregivers. Many fewer pathologists than hematologists documented MDS in their reports, which may be due to differential application of diagnostic criteria. No significant associations with documentation of MDS or subtype were seen for key demographic characteristics or treatment status at the time of the baseline questionnaire. However, numbers were small in some categories. 
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